Flag of the European Union EU Clinical Trials Register Help

Clinical trials for CCA

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Study title: 251: Esposito S, Marchisio P, Bosis S, Droghetti R, Mattina R, Principi N; Short Therapy Study Group. Comparative efficacy and safety of 5-day cefaclor and 10-day amoxycillin treatment of group A streptococcal pharyngitis in children. Int J Antimicrob Agents. 2002 Jul;20(1):28-33.
    Active substance: AMOXICILLIN
    Study summary document link (including results):
    View full study record
    Document reference: 46611
    Study title: 319: Aguilar A, Tinoco JC, Macias M, Huicho L, Levy J, Trujillo H, Lopez P, Pereira M, Maqbool S, Bhutta ZA, Sacy RA, Deacon S. Clinical and bacteriologic efficacy of amoxycillin b.d. (45 mg/kg/day) versus amoxycillin t.d.s (40 mg/kg/day) in children with group A beta-hemolytic streptococcal tonsillopharyngitis. J Chemother. 2000 Oct;12(5):396-405.
    Active substance: AMOXICILLIN
    Study summary document link (including results):
    View full study record
    Document reference: 46615
    Study title: 405: Feder HM Jr, Gerber MA, Randolph MF, Stelmach PS, Kaplan EL. Once-daily therapy for streptococcal pharyngitis with amoxicillin. Pediatrics. 1999 Jan;103(1):47-51.
    Active substance: AMOXICILLIN
    Study summary document link (including results):
    View full study record
    Document reference: 46617
    Study title: 441: Gopichand I, Williams GD, Medendorp SV, Saracusa C, Sabella C, Lampe JB, Garcia RE, Lebrun L, Goldfarb J. Randomized, single-blinded comparative study of the efficacy of amoxicillin (40 mg/kg/day) versus standard-dose penicillin V in the treatment of group A streptococcal pharyngitis in children. Clin Pediatr (Phila). 1998 Jun;37(6):341-6.
    Active substance: AMOXICILLIN
    Study summary document link (including results):
    View full study record
    Document reference: 46620
    Study title: A Controlled Study on the Effect of a Soluble Insert on Keratoconjunctivitis Sicca
    Active substance: ARTIFICIAL TEARS
    Study summary document link (including results):
    View full study record
    Document reference: 21867
    Study title: Long Term Study of the Effect of a Sustained Release Artificial Tear Substitute (SR-AT) on Keratoconjunctivitis Sicca;
    Active substance: ARTIFICIAL TEARS
    Study summary document link (including results):
    View full study record
    Document reference: 21868
    Study title: Randomized, multicenter open study comparing the efficacy of potassium-phenoxymethylpenicillin V three times daily for 10 days versus benzathine penicillin V twice daily for 5 days in the treatment of acute group A ß-hemolytic streptococcal tonsillopharyngitis in childrenClinical efficacy and tolerance of bacampicillin and amoxycillin suspensions in children with acute otitis media; J Int Med Res. 1989 Jan-Feb;17(1):41-7.
    Active substance: BENZATHINE BENZYLPENICILLIN
    Study summary document link (including results):
    View full study record
    Document reference: 22276
    Study title: Randomized, multicenter pilot study comparing the efficacy of potassium-phenoxymethylpenicillin granules for oral suspension 100.000 IU /kg/day tid for 10 days versus benzathine-phenoxymethylpenicillin suspension 100.000 IU /kg/day bid for 7 days versus benzathine-phenoxymethylpenicillin suspension 100.000 IU /kg/day bid for 5 days in the treatment of acute group A ß-hemolytic streptococcal tonsillopharyngitis in childrenEffect on urogenital flora of antibiotic therapy for urinary tract infection; Scand J Infect Dis. 1990;22(1):43-7.
    Active substance: BENZATHINE BENZYLPENICILLIN
    Study summary document link (including results):
    View full study record
    Document reference: 22275
    Study title: Randomized, multicenter open study comparing the efficacy of potassium-phenoxymethylpenicillin V three times daily for 10 days versus benzathine penicillin V twice daily for 5 days in the treatment of acute group A ß-hemolytic streptococcal tonsillopharyn
    Active substance: BENZATHINE PHENOXYMETHYLPENICILLIN
    Study summary document link (including results): DV 2-99_Final Report_010531.pdf
    View full study record
    Document reference: 41960
    Study title: Zaffanello-Marco, Zamboni-Giorgio, Fontana-Elena, Zoccante-Leonardo, Tato-Luciano. Regional Center for Neonatal Congenital Errors of Metabolism, Department of Pediatrics, University of Verona, Verona, Italy. A case of partial biotinidase deficiency associated with autism. Child neuropsychology : a journal on normal and abnormal development in childhood and adolescence, {Child-Neuropsychol}, Sep 2003, vol. 9, no. 3, p. 184-8, ISSN: 0929-7049.Zaffanello-Marco, Zamboni-Giorgio, Fontana-Elena, Zoccante-Leonardo, Tato-Luciano. Regional Center for Neonatal Congenital Errors of Metabolism, Department of Pediatrics, University of Verona, Verona, Italy. A case of partial biotinidase deficiency associated with autism. Child neuropsychology : a journal on normal and abnormal development in childho...
    Active substance: BIOTIN
    Study summary document link (including results):
    View full study record
    Document reference: 22604
    Study title: Evaluation of the efficacy and tolerance of RU51807 (cefpodoxime proxetil 8mg/kg/day) in children with group a beta haemolytic streptococcal tonsillitis/pharyngitis. A multicenter, international, randomized, open- label, comparative study vs penicillin V 75 000 IU/kg/day
    Active substance: CEFPODOXIME
    Study summary document link (including results): CEFPODOXIME STUDY FF8980737.xls
    View full study record
    Document reference: 47972
    Study title: Open label, non-comparative study of Cefotaxime (300 mg/kg/day) plus vancomycin (60 mg/kg/day) combination as first line treatment of pneumococcal meningitis in children aged from 3 months to 18 years
    Active substance: CEFOTAXIME
    Study summary document link (including results): Cefotaxime-Study 1.pdf
    View full study record
    Document reference: 47343
    Study title: A comparison cure and recurrence rates among patients with streptococcal tonsillopharyngitis treated with either cefprozil (500 mg QD) vs Cefaclor (250 mg TID) in the treatment of mild to moderate strep pharyngitis and tonsillitis.
    Active substance: CEFPROZIL
    Study summary document link (including results):
    View full study record
    Document reference: 23581
    Study title: A multi-center, comparative study of cefprozil and penicillin V in the treatment of mild to moderate streptococcal tonsillopharyngitis (final report on study AI414-084 - pediatric).
    Active substance: CEFPROZIL
    Study summary document link (including results): Protocol ai414-084 Cefprozil.pdf
    View full study record
    Document reference: 23575
    Study title: Cefpodoxime Proxetil - Mark A. Del Beccaro, MD - 1993 (Pediatric annals 22:3)Cefpodoxime Proxetil - Mark A. Del Beccaro, MD - 1993 (Pediatric annals 22:3)
    Active substance: CEFPODOXIME
    Study summary document link (including results):
    View full study record
    Document reference: 23557
    Study title: Cefpodoxime Proxetil versus penicillin V in the treatment of streptococcal pharyngitis in children - Nancy E. Kline, Mark W. Kline - 1991 (Current Therapeutic Research, Vol. 49, N° 5 )Cefpodoxime Proxetil versus penicillin V in the treatment of streptococcal pharyngitis in children - Nancy E. Kline, Mark W. Kline - 1991 (Current Therapeutic Research, Vol. 49, N° 5 )
    Active substance: CEFPODOXIME
    Study summary document link (including results):
    View full study record
    Document reference: 23560
    Study title: Cefpodoxime Proxetil vs penicillin V in pediatric streptococcal pharyngitis / tonsillitis - Adnan S. Dajani, MD, Susan L. Kessler, MD, Robert Mendelson, MD, Donald L. Udan, PharmD, Wesley Mark Todd, MD - 1993 (Pediatr Infect Dis J; 12: 275 - 279)Cefpodoxime Proxetil vs penicillin V in pediatric streptococcal pharyngitis / tonsillitis - Adnan S. Dajani, MD, Susan L. Kessler, MD, Robert Mendelson, MD, Donald L. Udan, PharmD, Wesley Mark Todd, MD - 1993 (Pediatr Infect Dis J; 12: 275 - 279)
    Active substance: CEFPODOXIME
    Study summary document link (including results):
    View full study record
    Document reference: 23561
    Study title: Cephalosporins are superior to penicillin for treatment of streptococcal tonsillopharyngitis: is the difference worth it? - Michael E. Pichichero, MD - 1993 (Pediatr Infec Dis J, 12: 268-74)Cephalosporins are superior to penicillin for treatment of streptococcal tonsillopharyngitis: is the difference worth it? - Michael E. Pichichero, MD - 1993 (Pediatr Infec Dis J, 12: 268-74)
    Active substance: CEFPODOXIME
    Study summary document link (including results):
    View full study record
    Document reference: 23563
    Study title: Boccazzi A, Tonelli P, Bellosta C, Careddu P. Clinical and pharmacological evaluation of a modified cefotaxime bid regimen versus traditional tid in pediatric lower respiratory tract infections. Diagn Microbiol Infect Dis. 1998 Dec;32(4):265-72.Boccazzi A, Tonelli P, Bellosta C, Careddu P. Clinical and pharmacological evaluation of a modified cefotaxime bid regimen versus traditional tid in pediatric lower respiratory tract infections. Diagn Microbiol Infect Dis. 1998 Dec;32(4):265-72.
    Active substance: CEFOTAXIME
    Study summary document link (including results):
    View full study record
    Document reference: 23464
    Study title: Comparison of cefpodoxime proxetil oral suspension (100 mg / 5 ml) (DoxefTM; U-76252; CS-807) and penicillin V potassium oral suspension in the treatment of acute streptococcal pharyngitis / tonsillitis in infants and children - M-1140-0028 - LM. Paxton
    Active substance: CEFPODOXIME
    Study summary document link (including results): CEFPODOXIME STUDY TR915590018.xls
    View full study record
    Document reference: 23523
    1  2  3  4  5  6  7  8  9  Next» Last»»
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 04 10:22:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA